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Abstract. Nanomedicine and Nanoinformatics are emerging disciplines 
with substantial challenges ahead. For instance, Nanomedicine involves 
complex and massive data analysis. Nanoinformatics could expand previous 
experiences in Biomedical Informatics with new features required to study 
different scientific biological and physical characteristics at a different level 
of complexity. ACTION-Grid is a project, funded by the European 
Commission, which aims to the creation of a collaborative environment in 
Biomedical and Nanomedical research among countries in Europe, Western 
Balkans, Latin America and North Africa. In this paper, we briefly review 
the concepts of Nanomedicine and Nanoinformatics and then we describe 
the activities of some of the ACTION-Grid consortium members 
considering those initiatives related to Nanomedicine..  
Keywords. Nanoinformatics, Nanomedicine, Knowledge Management, 
Text Mining.  
Introduction 
The impact of the nano-related disciplines on the scientific research world is increasing. The 
possibilities offered by the application of nanotechnology to fields like medicine surely will 
imply a change of trend in various aspects of these areas. This growth requires a constant 
effort to efficiently manage this rapid progress. 
The great interest of the scientific community in nanomedicine has already generated a 
large amount of information —i.e. documents and tools— that is normally unstructured and not 
organized. To improve the efficiency of research on nanomedicine-related areas, the scientific 
community should approach the problem considering various points of view, such as for 
instance:  
- Organize the current available material. It is important to create indexes of current 
research initiatives and the available resources that can be used and shared by research 
groups.  
- Focus the efforts on specific high-impact research directions. Some topics can be 
considered more relevant for a rapid progress of the area. Research effort should be 
focused on these themes. 
1.1. Nanomedicine and nanoinformatics 
NIH defines nanomedicine as a “highly specific medical intervention at the molecular scale 
for curing disease or repairing damaged tissues”. In general terms, nanomedicine is the 
application of nanotechnology to the medical domain. The possibilities that this area creates 
are impressive and range from the improvement of pharmaceutics products, making them 
more effective and reducing their contraindications, to the enhancement of the diagnostic 
precision or tissue replacement and repairing. There are also some secondary effects such as 
nanotoxicity, that should be analyzed before they are effectively applied in clinical routine. 
1.2. Nanoparticles and Nanotoxicity 
According to the ASTM standard definition a nanoparticle is any particle with lengths 
measured in nanometers (10-9 m) and range from 1 to 100 nm in two or three dimensions [1]. 
Recently nanoparticles started to be widely used in medical practice as diagnostic and 
therapeutic tools in order to understand, detect and treat diseases. To understand the toxicity 
of nanoparticles it is important to consider them as particles of very tiny size enabled to 
circulate through the blood, lymph or other paths in human, animal or any biological 
organism [2].  Exposure to them could have some unwanted consequences, some adverse 
effect, some temporary or permanent toxic result. 
There is a number of studies considering the toxicity of nanoparticles in both “in vitro” 
and “in vivo”. For example, Sayes and al. [3] used several types of nanoparticles for 
experiment with rats (in vivo) and selected tissue cultures (in vitro). However, very weak 
correlation between results of toxicity of particular particles in these two approaches was 
found. The in vivo approach is more complex, due to the fact that it should take care not only 
of dose and time dependency but also on potential multiple exposures and bioaccumulation. 
In vitro studies are more frequent, but willing the thorough understanding of kinetics and 
toxicology of nanoparticles, in vivo studies will be more appropriate. Any result identified in 
in vitro studies should be verified by in vivo studies. Such studies, description of their design, 
carrying out, and publishing results should be also standardized as is the custom in science 
[4,5]. 
Given the complexity of interactions and secondary effects that may appear, the 
implication of informatics tools and systems —such as health electronic records— will be 
important to address information management in this area. 
2. European Research in the framework 
ACTION-Grid (www.vph-action-grid.eu) is a European Commission-funded cooperative 
action aiming to the development of a collaborative environment among research groups in 
Europe, Latin America, Western Balkans and North Africa, which are working on 
Bioinformatics, Medical Informatics, Nanomedicine and High Performance and GRID 
computing. In the next section we present an overview on current efforts of the ACTION-Grid 
Consortium members related with nanomedicine. 
2.1. An inventory of informatics resources 
As stated above, nanomedicine implies an important information management problem that 
can be addressed by a novel discipline called Nanoinformatics. The latter involves the 
development of effective tools/technologies/methods for collecting, standardizing, integrating, 
analyzing and visualizing information relevant to nanomedicine including those data that can 
be relevant such as literature, physical-chemical properties, biological, clinical and 
toxicological effects [7]. In such context, we developed a method for the automatic creation of 
an index of Bioinformatics resources. This collection of tools, databases and services (in 
general “resources”) is an index of resources, created automatically from a set of scientific 
documents describing resources retrieved from internet. Each of these documents is analyzed 
and processed to extract relevant information.  
The method used to process documents is based on 4 steps [8,9]: i) the document is 
divided in sections corresponding to the title, the abstract and the article body; ii) Then the 
algorithm preprocesses the sentences belonging to the title and the abstract sections, 
eliminating stop words and reducing the remaining words to their root form; iii) the 
preprocessed text is given as input to a transition network that, applying morphological and 
syntactic patterns, extracts the name and the functionalities of the resource described in the 
paper given as input; iv) Finally, a second transition network uses the previous extracted 
information to classify the considered resource. 
Tools and databases about nanotechnology applied to medicine are currently in 
development and in some case their classification is still impossible. Then, it is needed to 
define what we consider as relevant information in nanomedicine domain. 
2.2. Lab- on-Chip & Proteomics-based Discovery of Biomarkers 
The importance of lab-on-chip technology, and of the engaged proteomics based discovery of 
biomarkers is made evident, among other, from a recent special issue of Nature [10], and 
respective articles related to microfluidic-based diagnostic technology [11]. A biomarker is an 
identified protein, which is correlated with the state of a particular disease or condition[12]. 
Biomarkers can be used for detection, diagnosis, treatment, monitoring, prognosis and drug 
discovery processes.  
An indicative example of a relative R&D approach in the field is the work carried out at 
FORTH concerned with validating the application of plasma protein profiling for early 
pancreatic cancer diagnosis by means of developing an innovative nano-technology based 
(lab-on-a-chip) platform integrated in a full proteomics analysis chain [13]. The model 
combines three modules: (a) The ‘bio’ module of the analysis chain gets as input blood 
sample, and provides the ‘nano’ part with a selected protein mixture; (b) The ‘nano’ module is 
the part related to the dedicated Lab-on-Chip device, MS experiment and analysis of related 
MS-data. (c) The ‘info’ part is related to the supporting information technology infrastructure 
and is utilized through a specially designed LIMS that manages both proteomic and clinical 
data, i.e., an integrated clinico-proteomics information management system [14]. LIMS 
encompasses an advanced data-mining module for the analysis of MS-data and the discovery 
of biomarkers.Various XML (eXtensible Markup Language) standards for proteomics have 
been developed in order to facilitate the capture, analysis, and distribution of proteomics data, 
such as mzXML [15,16]. The intent of mzXML is to encapsulate unprocessed, raw peak lists. 
A protein ‘profile reconstruction module’ for the quantification (from mass-spectrogram 
peaks) of targeted protein concentration levels [17] is provided reusing results of a previous 
project named LOCCANDIA. 
2.3. Micro and Nano-Arrays 
Microarrays represent a bridging development between micro and nanotechnology. At the 
microarray laboratory of the Medical Bioinformatics Dept. of ISCIII (MBD), we have been 
working for several years [18] in this scientific and technological interface between micro and 
nano technologies. The main efforts carried out up to now have been focused on two different 
lines. The first one is oriented towards improving the quality of the chemistry that it is used 
on the surfaces of the microarrays. The group has been testing different methodologies for 
treating glass slides to increase their affinity for the biological molecules that are more 
frequently immobilised (nucleic acids and proteins).  The second approach is represented by 
the use of biological machinery and robotics for the in-situ synthesis of biological molecules 
on the microarray surface.  The basis for this approach relies on the immobilization of 
biological molecules that can act as a substrate for the synthesis. We have applied this 
technology for the development of diagnostic assays [19] and the detection of microbial 
pathogens.  
2.4. Knowledge management in nanomedicine 
Knowledge management is a key component that will facilitate further advances in the 
field, classifying and making easily available the different resources to the research 
community. Our group has been working in structuring a framework that can accommodate 
and organize the increasing number of available resources (systems, methods, data, software 
tools and standards) in Nanomedicine [20].  The in-house knowledge management system 
(BIKMAS) that MBD has been using for several years [21] has been recently adapted to be 
able to incorporate and process all the new information coming from Nanomedicine research 
and development.  Using this new version of the software, it is possible to provide partners 
with up-to-date information related with advances of the application of nanotechnology in 
Medicine.  
2.5. Converging technologies: Nano Bio Info Cogno (NBIC) 
At the MBD, researchers are working in a model called Info-POC. Info-POC stands for 
Information-enhanced Point-Of-Care diagnostic system. This research aims to demonstrate 
the concept of convergence among NBIC technologies, with the goal of creating a new 
research framework for the development of diagnostic methods at the point of care, in the 
context of genomic medicine. The systems includes: (1) the study of new “in info” diagnosis 
and treatment methods, based on biomolecular automata. (2) The analysis of differential gene 
expression in colon cancer and the detection of microorganisms "in vitro" by mean of 
microarrays. They will be complemented with the biomolecular automata systems for 
diagnosis and with processes of information retrieval from Internet with the aim of putting 
into context the results of the system. (3) the design of new “in silico” methods, based on the 
Semantic Web, for enhancing private and public data sources retrieval and mining.  These 
results, previously began in a Spanish national network called COMBIOMED, will be 
integrated with computerized protocols for diagnosis, treatment and management of patients 
with particular genetic (cancer) and infectious diseases. 
3. Results and Conclusions 
The ACTION-Grid project aims to achieve important objectives to foster research in all 
the mentioned areas and facilitate knowledge exchanges among heterogeneous research 
groups. Currently, preliminary results are already available, contributing to the construction of 
the resources index. Each ACTION-Grid consortium members is also obtaining results on 
their specified research lines as described in the previous sections of this article. 
Nanoinformatics can become a key topic for future medical research activities. The 
scientific community should facilitate and enhance synergies between this discipline and 
classical disciplines like Medical Informatics and Bioinformatics. Lessons learned for various 
decades in these two disciplines can be valuable to develop a sound agenda and strong 
foundations for Nanoinformatics. 
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